Literature DB >> 15886157

Vaccine advance-purchase agreements for low-income countries: practical issues.

Ernst R Berndt1, John A Hurvitz.   

Abstract

There are strong theoretical arguments for the creation of advance-purchase agreements to increase incentives for the development and production of vaccines for diseases concentrated in low-income countries. A Center for Global Development working group recently concluded that such agreements could be implemented successfully. We consider the practical economic and legal arrangements for such advance-purchase commitments. We identify several practical issues that we believe the public health and policy community should consider further in the design of an advance-purchase commitment.

Mesh:

Substances:

Year:  2005        PMID: 15886157     DOI: 10.1377/hlthaff.24.3.653

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  5 in total

1.  The special case of gene therapy pricing.

Authors:  Troyen A Brennan; James M Wilson
Journal:  Nat Biotechnol       Date:  2014-09       Impact factor: 54.908

2.  'If I had a hedge fund, I would cure diabetes': endogenous mechanisms for creating public goods.

Authors:  John Liechty; Stefan Wuyts
Journal:  SN Bus Econ       Date:  2021-09-06

3.  In global health research, is it legitimate to stop clinical trials early on account of their opportunity costs?

Authors:  James V Lavery; Peter A Singer; Renee Ridzon; Jerome A Singh; Arthur S Slutsky; Joseph J Anisko; David Buchanan
Journal:  PLoS Med       Date:  2009-06-09       Impact factor: 11.069

4.  Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model.

Authors:  David M Brogan; Elias Mossialos
Journal:  Global Health       Date:  2013-11-07       Impact factor: 4.185

Review 5.  The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats.

Authors:  Michael Osterholm; Kristine Moore; Julie Ostrowsky; Kathleen Kimball-Baker; Jeremy Farrar
Journal:  Lancet Infect Dis       Date:  2015-10-30       Impact factor: 25.071

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.